At the 20th Congress of the European Hematology Association (EHA), Barbara Eichhorst, MD, of the University of Cologne, Cologne, Germany, discusses ongoing clinical studies by the German CLL Study Group (GCLLSG) that are investigating new therapies for patients with chronic lymphocytic leukaemia (CLL), including obinutuzumab in combination with chlorambucil; a watch-and-wait strategy; and a four-arm study comparing standard chemotherapy versus non-chemotherapy-containing regimens.
